Related references
Note: Only part of the references are listed.Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers
Lisa Seitz et al.
INVESTIGATIONAL NEW DRUGS (2019)
VEGF-A Inhibition as a Potential Therapeutic Approach in Merkel Cell Carcinoma
Thibault Kervarrec et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Shailender Bhatia et al.
CLINICAL CANCER RESEARCH (2019)
Blocking don't eat me signal of CD47-SIRPα in hematological malignancies, an in-depth review
Atlantis Russ et al.
BLOOD REVIEWS (2018)
Safety Profile of Avelumab in Patients With Advanced Solid Tumors: A Pooled Analysis of Data From the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel 200 Clinical Trials
Karen Kelly et al.
CANCER (2018)
Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus
Ioannis Gavvovidis et al.
CLINICAL CANCER RESEARCH (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients
Linde M. van Veenendaal et al.
JOURNAL OF SURGICAL ONCOLOGY (2018)
Merkel Cell Carcinoma, Version 1.2018 Clinical Practice Guidelines in Oncology
Christopher K. Bichakjian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Are there multiple cells of origin of Merkel cell carcinoma?
J. C. Sunshine et al.
ONCOGENE (2018)
The Human Polyomavirus Middle and Alternative T-Antigens; Thoughts on Roles and Relevance to Cancer
Els van der Meijden et al.
FRONTIERS IN MICROBIOLOGY (2018)
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial
Sandra P. D'Angelo et al.
JAMA ONCOLOGY (2018)
In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series
Melody J. Xu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TIGIT: a novel immunotherapy target moving from bench to bedside
Benjamin L. Solomon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Comprehensive genomic profiling of advanced Merkel cell carcinoma to reveal insights into immunotherapy response
Todd Cory Knepper et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study
Jurgen C. Becker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372
Shailender Bhatia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP)
John Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358
Suzanne Louise Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
K. G. Paulson et al.
NATURE COMMUNICATIONS (2018)
Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
Kevin Sek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study
Kelly G. Paulson et al.
CANCER (2017)
Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma
Paul Nghiem et al.
FUTURE ONCOLOGY (2017)
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
C. Lance Cowey et al.
FUTURE ONCOLOGY (2017)
Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas
Maria del Carmen Gonzalez-Vela et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Natural killer cell response is a predictor of good outcome in MCPyV+ Merkel cell carcinoma: A case series of 23 patients
Valerie Laniosz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients
J. K. Winkler et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials
Manni Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Human Tumor-infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Louise A. Elliott et al.
FRONTIERS IN IMMUNOLOGY (2017)
Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)
Suzanne L. Topalian et al.
CANCER RESEARCH (2017)
Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System
Kelly L. Harms et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma
M. Samimi et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma
Noreen M. Walsh et al.
HUMAN PATHOLOGY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation
Paul W. Harms et al.
MODERN PATHOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
Jayasri G. Iyer et al.
CANCER MEDICINE (2016)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Andreas Lundqvist et al.
Journal for ImmunoTherapy of Cancer (2016)
Metastatic Merkel cell carcinoma response to nivolumab
Frances M. Walocko et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma
Cathrin Ritter et al.
SCIENTIFIC REPORTS (2016)
The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma
Paul William Harms et al.
CANCER RESEARCH (2015)
Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study
S. Bhatia et al.
EUROPEAN JOURNAL OF CANCER (2015)
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline
Celeste Lebbe et al.
EUROPEAN JOURNAL OF CANCER (2015)
Risk of Merkel Cell Carcinoma After Solid Organ Transplantation
Christina A. Clarke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Risk of Merkel Cell Carcinoma After Solid Organ Transplantation
Christina A. Clarke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
CD8+ Lymphocyte Intratumoral Infiltration as a Stage-Independent Predictor of Merkel Cell Carcinoma Survival A Population-Based Study
Kelly G. Paulson et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Interleukin 12: still a promising candidate for tumor immunotherapy?
Witold Lasek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Rikke Lyngaa et al.
CLINICAL CANCER RESEARCH (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Vitamin D deficiency is associated with greater tumor size and poorer outcome in Merkel cell carcinoma patients
M. Samimi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma
Patrick J. Cimino et al.
MODERN PATHOLOGY (2014)
Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I
Aude G. Chapuis et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma
Kelly G. Paulson et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Inflammatory Cell Distribution in Primary Merkel Cell Carcinoma
Rachel Wheat et al.
CANCERS (2014)
Age-Specific Seroprevalences of Merkel Cell Polyomavirus, Human Polyomaviruses 6, 7, and 9, and Trichodysplasia Spinulosa-Associated Polyomavirus
Jerome T. J. Nicol et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
Olga K. Afanasiev et al.
CLINICAL CANCER RESEARCH (2013)
Systemic Immune Suppression Predicts Diminished Merkel Cell Carcinoma-Specific Survival Independent of Stage
Kelly G. Paulson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses
Mitra Dowlatshahi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Unknown primary Merkel cell carcinoma: 23 new cases and a review
Tina I. Tarantola et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
Evan J. Lipson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Merkel Cell Carcinoma: A Virus-Induced Human Cancer
Yuan Chang et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 7 (2012)
Type I and II IFNs Inhibit Merkel Cell Carcinoma via Modulation of the Merkel Cell Polyomavirus T Antigens
Christoph Willmes et al.
CANCER RESEARCH (2012)
Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Harri Sihto et al.
CLINICAL CANCER RESEARCH (2012)
Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus
Scott J. Rodig et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Merkel cell carcinoma induces lymphatic microvessel formation
Siegfried Werchau et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Diagnostic Biopsy Does Not Commonly Induce Intratumoral CD8 T Cell Infiltration in Merkel Cell Carcinoma
Shinichi Koba et al.
PLOS ONE (2012)
Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus
Caroline Biver-Dalle et al.
ACTA ONCOLOGICA (2011)
Abscopal Effect in a Patient With Metastatic Merkel Cell Carcinoma Following Radiation Therapy: Potential Role of Induced Antitumor Immunity
Shane E. Cotter et al.
ARCHIVES OF DERMATOLOGY (2011)
Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood
Jayasri G. Iyer et al.
CLINICAL CANCER RESEARCH (2011)
Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival
Kelly G. Paulson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Skin cancers associated with autoimmune conditions among elderly adults
E. Lanoy et al.
BRITISH JOURNAL OF CANCER (2010)
Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients
Kelly G. Paulson et al.
CANCER RESEARCH (2010)
Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinoma
Thomas Jouary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Clonal integration of a polyomavirus in human Merkel cell carcinoma
Huichen Feng et al.
SCIENCE (2008)
Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapy
Kelly M. Garneski et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Merkel cell carcinoma: Prognosis and treatment of patients from a single institution
PJ Allen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Merkel cell carcinoma and HIV infection
EA Engels et al.
LANCET (2002)
Hit-and-run transformation by adenovirus oncogenes
M Nevels et al.
JOURNAL OF VIROLOGY (2001)
Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: Case series and review of 204 cases
PTH Tai et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
